Back to results
US 2023/0141284 A1Published application
Cancer therapeutic method
AssigneeOno Pharmaceutical Co., Ltd.
InventorsKazuhiko TAKEDA, Ryohei MIYATA, Tomoya KOIKE, Akira KATSUBE
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeOno Pharmaceutical Co., Ltd.
InventorsKazuhiko TAKEDA, Ryohei MIYATA, Tomoya KOIKE, Akira KATSUBE
Estimating the term…
A prescription capable of avoiding induction of inflammatory cytokine production caused by a STING agonistic compound in a cancer patient, when suppressing the progression of, suppressing the recurrence of and/or treating cancer by the STING agonistic compound, is provided. A prescription that a STING agonistic compound is administered in combination with an adrenal corticosteroid when suppressing the progression of, suppressing the recurrence of and/or treating cancer. Methods for avoiding an induction of inflammatory cytokine production by administering the prescription in combination with an adrenal corticosteroid when administering a STING agonistic compound at reduced dosage in combination with an anti-neoplastic agent.
A method for suppressing the progression of, suppressing the recurrence of and/or treating cancer in a subject in need thereof, comprising administering an effective amount of an agent in combination with an adrenal corticosteroid, wherein the agent comprises a STING stimulation of interferon genes) agonistic compound as an active ingredient, and
Dependencies are inferred from the claim text.